Inside Haematologica: Caution in the use of thalidomide for treatment of hematologic disorders

Haematologica

Volumn 87, Issue 4, 2002, Pages 345-346

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

DEEP VEIN THROMBOSIS; DRUG INDICATION; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; SHORT SURVEY;

HEMATOLOGIC DISEASES; HUMANS; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0036214041     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (22)

1. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma
2. Low-dose of thalidomide in the treatment of refractory myeloma
3. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma
4. Thalidomide treatment of resistant or relapsed multiple myeloma patients
5. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation
6. The irreplaceable image. Thalidomide in refractory myeloma patients: Early changes in bone marrow cellularity
7. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia
8. Thalidomide in multiple myeloma: State of art
9. Advantages of using thalidomide for the management of refractory myeloma patients
10. Thalidomide and thrombosis in patients with multiple myeloma
11. Diabetic foot disease in a patient with multiple myeloma receiving thalidomide
12. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
13. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives
14. Inherited thrombophilic risk factors in a large cohort of individuals referred to Italian thrombophilia centers: Distinct roles in different clinical settings
15. Quantification of D-dimer using a new fully automated assay: Its application for the diagnosis of deep vein thrombosis
16. A rapid D-dimer assay in patients presenting at the emergency room with suspected acute venous thrombosis: Accuracy and relation to clinical variables
17. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia
18. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
19. Thalidomide in agnogenic and secondary myelofibrosis
20. Thalidomide for the treatment of patients with myelodysplastic syndromes
21. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes
22. Myelodysplastic syndromes: Recent advances